文献速递主动脉疾病

使用Najuta胸主动脉开窗支架在远端主动脉弓动脉瘤血管内治疗中加强近端锚定的临床影响

Clinical impact of proximal fixation augmentation using the Najuta thoracic fenestrated stent graft during endovascular treatment for distal aortic arch aneurysm.
PubMed 文献 · J Vasc Surg · 2024-05-13

单中心回顾性研究纳入386例胸主动脉疾病TEVAR病例,比较标准组(zone 2锚定)与加强组(zone 0使用Najuta开窗支架加zone 2 TEVAR)的临床结局。加强组因Ia型内漏再干预率显著低于标准组(36个月和60个月均为100.0% vs 标准组79.2%和65.2%,P = .0087),作者认为近端锚定加强可有效预防术后晚期Ia型内漏。

要点

  • 加强组36个月和60个月免于Ia型内漏再干预率均为100.0%,标准组分别为79.2%和65.2%(P = .0087)。
  • 两组技术成功率均为100%,30天死亡率及逆行性A型夹层均为零。
  • 加强组主要不良事件2例(卒中1例、截瘫1例),标准组3例(卒中2例、肱动脉假性动脉瘤1例)。

核心结论

  • 在远端弓部动脉瘤TEVAR中使用Najuta开窗支架加强近端锚定,可有效预防术后晚期Ia型内漏。

研究设计与样本

  • 单中心回顾性研究,纳入2013年1月至2020年12月386例胸主动脉疾病TEVAR病例。
  • 标准组为TEVAR锚定于zone 2的胸主动脉瘤患者,加强组为在zone 2 TEVAR基础上使用Najuta开窗支架锚定于zone 0的患者。
  • 标准组41例,加强组30例;主要终点为术后Ia型内漏的二次干预。

主要发现

  • 标准组与加强组平均动脉瘤大小分别为54.5 mm和57.3 mm(P = .23),近端锚定区长度分别为16.8 mm和17.4 mm(P = .65)。
  • 两组技术成功率均为100%;标准组主要不良事件3例(卒中2例、肱动脉假性动脉瘤1例),加强组2例(卒中1例、截瘫1例)。
  • 两组均无30天死亡及逆行性A型夹层;标准组平均观察46个月(范围1-123个月),加强组35个月(范围1-73个月)。
  • 术后36个月和60个月免于动脉瘤相关死亡:标准组均为97.6%,加强组均为100.0%(P = .39)。
  • 术后36个月和60个月免于Ia型内漏再干预:标准组分别为79.2%和65.2%,加强组均为100.0%(P = .0087),加强组再干预显著减少。

临床怎么用

  • 作者认为,在远端弓部动脉瘤TEVAR中使用Najuta开窗支架加强近端锚定可有效预防术后晚期Ia型内漏。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prevention of late type Ia endoleaks is the main concern in thoracic endovascular aortic aneurysm repair (TEVAR) for thoracic aortic aneurysm. Since 2017, we have performed zone 0 TEVAR with proximal fixation augmentation using a Najuta thoracic fenestrated stent graft in addition to zone 2 TEVAR for distal arch aneurysms. We report the early and midterm outcomes of TEVAR performed using this strategy. METHODS: This single-center retrospective study enrolled 386 cases of TEVAR for thoracic aortic disease between January 2013 and December 2020. Patients with thoracic aortic aneurysm treated by TEVAR landing at zone 2 was referred to as the standard group, whereas those treated by TEVAR landing at zone 0 using a Najuta fenestrated stent graft in addition to zone 2 TEVAR was referred to as the augmentation group. We retrospectively compared the clinical outcomes between the two groups. The primary end point was secondary intervention for postoperative type Ia endoleaks. Secondary end points were technical success, aneurysm-related death, and major adverse events (MAEs), including stroke, paraplegia, endoleaks, and secondary interventions. RESULTS: We performed TEVAR in 41 and 30 cases in the standard and augmentation groups, respectively. The mean aneurysm sizes in the standard and augmentation groups were 54.5 and 57.3 mm (P = .23), and the proximal neck lengths were 16.8 and 17.4 mm (P = .65), respectively. The anatomical characteristics seemed to be similar in both groups. The technical success rate in both groups was 100%. Three cases in the standard group had MAEs, including two stroke and one brachial artery pseudoaneurysm; whereas two cases had MAEs in the augmentation group, including one stroke and one paraplegia. There was no 30-day mortality or retrograde type A dissection in both groups. The mean observation periods in the standard and augmentation groups were 46 months (range, 1-123 months) and 35 months (range, 1-73 months), respectively. At 36 and 60 months after the procedure, the freedom from aneurysm-related death was 97.6% and 97.6% in the standard group, 100.0% and 100.0% in the augmentation group (P = .39); and the freedom from reintervention for type Ia endoleaks was 79.2% and 65.2% in the standard group, 100.0% and 100.0% in the augmentation group (P = .0087). A statistically significant decrease in reinterventions for type Ia endoleaks was observed in the augmentation group. CONCLUSIONS: Proximal fixation augmentation using the Najuta fenestrated stent graft during TEVAR for distal arch aneurysm is effective in preventing the postoperative late type Ia endoleaks.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Fukushima S, Ohki T, Tachihara H, et al. Clinical impact of proximal fixation augmentation using the Najuta thoracic fenestrated stent graft during endovascular treatment for distal aortic arch aneurysm. J Vasc Surg. 2024. PMID: 38750942. doi:10.1016/j.jvs.2024.04.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。